MD1419F2 - Complecsi de incluziune pe baza de SIN-1A si ciclodextrina, compozitii farmaceutice si truse pe baza lor, procedeu de preparare a complecsilor de incluziune si metoda de tratament - Google Patents

Complecsi de incluziune pe baza de SIN-1A si ciclodextrina, compozitii farmaceutice si truse pe baza lor, procedeu de preparare a complecsilor de incluziune si metoda de tratament

Info

Publication number
MD1419F2
MD1419F2 MD95-0440A MD950440A MD1419F2 MD 1419 F2 MD1419 F2 MD 1419F2 MD 950440 A MD950440 A MD 950440A MD 1419 F2 MD1419 F2 MD 1419F2
Authority
MD
Moldova
Prior art keywords
sin
complexes
cyclodextrin
base
kits
Prior art date
Application number
MD95-0440A
Other languages
English (en)
Other versions
MD1419G2 (ro
MD950440A (ro
Inventor
Joseph Geczy
Andrasne Vikmon
Jozsef Szejtli
Lajos Szente
Julianna Szeman
Original Assignee
Therabel Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Research Sa filed Critical Therabel Research Sa
Publication of MD950440A publication Critical patent/MD950440A/ro
Publication of MD1419F2 publication Critical patent/MD1419F2/ro
Publication of MD1419G2 publication Critical patent/MD1419G2/ro

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MD95-0440A 1994-04-26 1995-04-25 Complecşi de incluziune pe bază de SIN-1A şi ciclodextrină, compoziţii farmaceutice şi truse pe baza lor, procedeu de preparare a complecşilor de incluziune şi metodă de tratament MD1419G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9401183A HU218280B (en) 1994-04-26 1994-04-26 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
PCT/HU1995/000011 WO1995029172A1 (en) 1994-04-26 1995-04-25 N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes

Publications (3)

Publication Number Publication Date
MD950440A MD950440A (ro) 1997-10-31
MD1419F2 true MD1419F2 (ro) 2000-02-29
MD1419G2 MD1419G2 (ro) 2000-11-30

Family

ID=10985114

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0440A MD1419G2 (ro) 1994-04-26 1995-04-25 Complecşi de incluziune pe bază de SIN-1A şi ciclodextrină, compoziţii farmaceutice şi truse pe baza lor, procedeu de preparare a complecşilor de incluziune şi metodă de tratament

Country Status (32)

Country Link
US (1) US5698535A (ro)
EP (1) EP0705255B1 (ro)
JP (1) JP3434828B2 (ro)
KR (1) KR960703404A (ro)
CN (1) CN1060164C (ro)
AT (1) ATE197708T1 (ro)
AU (1) AU694219B2 (ro)
BG (1) BG61974B1 (ro)
BR (1) BR9506155A (ro)
CA (1) CA2163539C (ro)
CZ (1) CZ316395A3 (ro)
DE (1) DE69519463T2 (ro)
DK (1) DK0705255T3 (ro)
ES (1) ES2153897T3 (ro)
FI (1) FI956156A7 (ro)
GR (1) GR3035356T3 (ro)
HR (1) HRP950249A2 (ro)
HU (1) HU218280B (ro)
IL (1) IL113491A (ro)
LT (1) LT4167B (ro)
LV (1) LV11543B (ro)
MD (1) MD1419G2 (ro)
NO (1) NO311030B1 (ro)
NZ (1) NZ285149A (ro)
PL (1) PL312183A1 (ro)
PT (1) PT705255E (ro)
RO (1) RO114449B1 (ro)
RU (1) RU2136698C1 (ro)
SI (1) SI0705255T1 (ro)
SK (1) SK155195A3 (ro)
WO (1) WO1995029172A1 (ro)
YU (1) YU25995A (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3119C2 (ro) * 2000-02-24 2007-04-30 Therabel Pharmaceuticals Limited Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
CA2391008C (en) * 1999-11-12 2009-12-22 Pitha & Pitha Llc Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
RU2332425C2 (ru) * 2002-09-06 2008-08-27 Инсёрт Терапьютикс, Инк. Полимеры на основе циклодекстрина для доставки терапевтических средств
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
WO2004032862A2 (en) * 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2503888A4 (en) * 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
CN116249522A (zh) * 2020-07-20 2023-06-09 深圳迈瑞生物医疗电子股份有限公司 一种组合物的血小板解聚用途、解聚试剂及解聚方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780180A (en) 1971-02-04 1973-12-18 Sandoz Ag N-substituted amino-n-nitroso-aminoace-tonitriles in the treatment of hypertension
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
HU211648A9 (en) * 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
AU668107B2 (en) * 1991-09-24 1996-04-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3119C2 (ro) * 2000-02-24 2007-04-30 Therabel Pharmaceuticals Limited Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei

Also Published As

Publication number Publication date
EP0705255A1 (en) 1996-04-10
EP0705255B1 (en) 2000-11-22
IL113491A0 (en) 1995-07-31
FI956156A0 (fi) 1995-12-20
DK0705255T3 (da) 2000-12-11
PT705255E (pt) 2001-05-31
MD1419G2 (ro) 2000-11-30
LV11543B (en) 1996-12-20
HU218280B (en) 2000-07-28
HRP950249A2 (en) 1997-10-31
RO114449B1 (ro) 1999-04-30
AU2415995A (en) 1995-11-16
NZ285149A (en) 1998-06-26
LV11543A (lv) 1996-10-20
NO955283L (no) 1995-12-22
BG61974B1 (bg) 1998-11-30
CA2163539A1 (en) 1995-11-02
HUT70750A (en) 1995-10-30
ES2153897T3 (es) 2001-03-16
DE69519463D1 (de) 2000-12-28
HU9401183D0 (en) 1994-07-28
FI956156A7 (fi) 1995-12-20
NO955283D0 (no) 1995-12-22
AU694219B2 (en) 1998-07-16
SI0705255T1 (en) 2001-04-30
NO311030B1 (no) 2001-10-01
YU25995A (sh) 1998-08-14
PL312183A1 (en) 1996-04-01
US5698535A (en) 1997-12-16
RU2136698C1 (ru) 1999-09-10
BR9506155A (pt) 1996-04-16
JP3434828B2 (ja) 2003-08-11
LT95133A (en) 1996-10-25
IL113491A (en) 2002-03-10
LT4167B (en) 1997-06-25
CN1128028A (zh) 1996-07-31
CA2163539C (en) 2003-04-01
JPH09503546A (ja) 1997-04-08
WO1995029172A1 (en) 1995-11-02
GR3035356T3 (en) 2001-05-31
MD950440A (ro) 1997-10-31
ATE197708T1 (de) 2000-12-15
CZ316395A3 (en) 1996-05-15
DE69519463T2 (de) 2001-06-28
SK155195A3 (en) 1997-05-07
CN1060164C (zh) 2001-01-03
KR960703404A (ko) 1996-08-17
BG100313A (bg) 1996-07-31

Similar Documents

Publication Publication Date Title
PT788350E (pt) Formacao de particulas pequenas
AU2001255709A1 (en) Acylated cyclodextrin guest inclusion complexes
CA2163539A1 (en) N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes
AU4161399A (en) Nucleation and growth of magnetic metal oxide nanoparticles and its use
NO307445B1 (no) Farmasøytiske preparater inneholdende nanokapsler og fremgangsmõte for fremstilling derav
CZ16395A3 (en) Inclusion complexes of nimesulid salts of alkali metals and alkaline earth metals with cyclodextrins, process of their preparation and pharmaceutical compositions containing thereof
DE60208784D1 (de) Clathrat von azithromycin-hydrat mit 1,2-propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
AU4718596A (en) Novelly substituted dtpa derivatives, metal complexes thereof, pharmaceuticals containing these complexes, diagnostic and therapeutic uses thereof and methods for preparing the complexes and pharmaceuticals
MY121175A (en) Ciclesonide-containing aqueous pharmaceutical composition
EP1353737A4 (en) PH-STABLE ACTIVE CARBON
AU1131288A (en) A method for making and a slow release composition for abating acid water formation
EP0743283A3 (en) Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes
JPS61277610A (ja) 浴用剤
JPH069820A (ja) 可溶性テルル組成物
Lim et al. The Effect of $ H^+ $ on Reduction of $[Co (NH_3) _4 (C_2O_4)]^+ $ with $[Fe (H_2O) _6]^{2+} $
NL171259B (nl) Werkwijze voor de bereiding van aceetaldehyde door oxydatie van etheen met zuurstof in waterig milieu, dat palladium- en koperzouten bevat.
UA43783A (uk) Глутамілтриптофан металокомплекси, що проявляють імуностимулюючі властивості та спосіб їх одержання
JPS63229056A (ja) 脱臭剤

Legal Events

Date Code Title Description
PD99 Pending application